A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
About the study
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- * Diagnosis of HeFH or premature CAD
- * Females of non-childbearing potential or males
EXCLUSION CRITERIA
Exclusion Criteria:
- * Homozygous familial hypercholesterolemia
- * Active or history of chronic liver disease
- * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- * Clinically significant or abnormal laboratory values as defined by the protocol
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Heterozygous Familial Hypercholesterolemia,Premature Coronary Heart Disease
Age (in years)
18 - 65
Phase
PHASE1
Participants Needed
36
Est. Completion Date
Aug 31, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Verve Therapeutics, Inc.
ClinicalTrials.gov NCT Identifier
NCT06164730
Study Number
VT-10201
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?